|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alamgeer M, Ganju V and Watkins DN: Novel
therapeutic targets in non-small cell lung cancer. Curr Opin
Pharmacol. 13:394–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Savas P, Hughes B and Solomon B: Targeted
therapy in lung cancer: IPASS and beyond, keeping abreast of the
explosion of targeted therapies for lung cancer. J Thorac Dis. 5
Suppl 5:S579–S592. 2013.PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
Meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arteaga CL: The epidermal growth factor
receptor: From mutant oncogene in nonhuman cancers to therapeutic
target in human neoplasia. J Clin Oncol. 19 Suppl 1:32S–40S.
2001.PubMed/NCBI
|
|
7
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang JC, Hirsh V, Schuler M, Yamamoto N,
O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey
D, et al: Symptom control and quality of life in LUX-Lung 3: A
phase III study of afatinib or cisplatin/pemetrexed in patients
with advanced lung adenocarcinoma with EGFR mutations. J Clin
Oncol. 31:3342–3350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balak MN, Gong Y, Riely GJ, Somwar R, Li
AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, et al:
Novel D761Y and common secondary T790M mutations in epidermal
growth factor receptor-mutant lung adenocarcinomas with acquired
resistance to kinase inhibitors. Clin Cancer Res. 12:6494–6501.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:pp. 20932–20937. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Camidge DR, Pao W and Sequist LV: Acquired
resistance to TKIs in solid tumours: Learning from lung cancer. Nat
Rev Clin Oncol. 11:473–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohashi K, Sequist LV, Arcila ME, Moran T,
Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et
al: Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad Sci USA. 109:pp. E2127–E2133. 2012;
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sacher AG, Jänne PA and Oxnard GR:
Management of acquired resistance to epidermal growth factor
receptor kinase inhibitors in patients with advanced non-small cell
lung cancer. Cancer. 120:2289–2298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zakowski MF, Ladanyi M and Kris MG;
Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome
Group, : EGFR mutations in small-cell lung cancers in patients who
have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mandel P and Metais P: Les acides
nucléiques du plasma sanguine chez l'homme. CR Seances Soc Biol
Fil. 142:241–243. 1948.(In Undetermined Language).
|
|
26
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
27
|
Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang
F, Xu L and Yin R: Circulating tumor DNA Is effective for the
detection of EGFR mutation in non-small cell lung cancer: A
meta-analysis. Cancer Epidemiol Biomarkers Prev. 24:206–212. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen KZ, Lou F, Yang F, Zhang JB, Ye H,
Chen W, Guan T, Zhao MY, Su XX, Shi R, et al: Circulating tumor DNA
detection in early-stage non-small cell lung cancer patients by
targeted sequencing. Sci Rep. 6:319852016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Beaver JA, Jelovac D, Balukrishna S,
Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J,
Blair BG, et al: Detection of cancer DNA in plasma of patients with
early-stage breast cancer. Clin Cancer Res. 20:2643–2650. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY,
Ni J, Zhang HP, Zhang L, Luo J, Zhang J, et al: Plasma EGFR T790M
ctDNA status is associated with clinical outcome in advanced NSCLC
patients with acquired EGFR-TKI resistance. Sci Rep. 6:209132016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sorensen BS, Wu L, Wei W, Tsai J, Weber B,
Nexo E and Meldgaard P: Monitoring of epidermal growth factor
receptor tyrosine kinase inhibitor-sensitizing and resistance
mutations in the plasma DNA of patients with advanced non-small
cell lung cancer during treatment with erlotinib. Cancer.
120:3896–3901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
21:560–562. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H and Durbin R: Fast and accurate
long-read alignment with Burrows-Wheeler transform. Bioinformatics.
26:589–595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome
Project Data Processing Subgroup, : The Sequence Alignment/Map
format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koboldt DC, Larson DE and Wilson RK: Using
VarScan 2 for germline variant calling and somatic mutation
detection. Curr Protoc Bioinformatics. 44:15.4.1–17. 2013.
View Article : Google Scholar
|
|
38
|
Thress KS, Brant R, Carr TH, Dearden S,
Jenkins S, Brown H, Hammett T, Cantarini M and Barrett JC: EGFR
mutation detection in ctDNA from NSCLC patient plasma: A
cross-platform comparison of technologies to support the clinical
development of AZD9291. J Clin Oncol. 90:509–515. 2015.
|
|
39
|
Xu T, Kang X, You X, Dai L, Tian D, Yan W,
Yang Y, Xiong H, Liang Z, Zhao GQ, et al: Cross-platform comparison
of four leading technologies for detecting EGFR mutations in
circulating tumor dna from non-small cell lung carcinoma patient
plasma. Theranostics. 7:1437–1446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sacher AG, Paweletz C, Dahlberg SE, Alden
RS, O'Connell A, Feeney N, Feeney N, Mach SL, Jänne PA and Oxnard
GR: Prospective validation of rapid plasma genotyping for the
detection of EGFR and KRAS mutations in advanced lung cancer. JAMA
Oncol. 2:1014–1022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fenizia F, De Luca A, Pasquale R, Sacco A,
Forgione L, Lambiase M, Iannaccone A, Chicchinelli N, Franco R,
Rossi A, et al: EGFR mutations in lung cancer: From tissue testing
to liquid biopsy. Future Oncol. 11:1611–1623. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kohler C, Barekati Z, Radpour R and Zhong
XY: Cell-free DNA in the circulation as a potential cancer
biomarker. Anticancer Res. 31:2623–2628. 2011.PubMed/NCBI
|
|
46
|
Chaft JE, Oxnard GR, Sima CS, Kris MG,
Miller VA and Riely GJ: Disease flare after tyrosine kinase
inhibitor discontinuation in patients with EGFR-mutant lung cancer
and acquired resistance to erlotinib or gefitinib: Implications for
clinical trial design. Clin Cancer Res. 17:6298–6303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nishino K, Imamura F, Morita S, Mori M,
Komuta K, Kijima T, Namba Y, Kumagai T, Yamamoto S, Tachibana I, et
al: A retrospective analysis of 335 Japanese lung cancer patients
who responded to initial gefitinib treatment. Lung Cancer.
82:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J, Fujimoto J, Zhang J, Wedge DC,
Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor
heterogeneity in localized lung adenocarcinomas delineated by
multiregion sequencing. Science. 346:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
